Dean's List: New Funding Awards
Dean's List:
New Funding Awards
Notable and novel scientific awards to celebrate.
June 2025New Federal Awards | |||
| Alexander Boyden | Pathology | NIH R21 2 years | Gamma herpesvirus impact on required B cell:CD4 T interactions in a B cell-dependent, antibody-independent mouse model of multiple sclerosis |
| Alexander Claussen | Otolaryngology | NIH K08 5 years | Defining the Mechanisms and Clinical Impact of Neo-ossification after Cochlear Implantation |
| Karen Cyndari | Emergency Medicine | NIH K08 5 years | Synovium Immunoprivilege and the Modulation of Resident Synovial Macrophage Functions in Lyme Arthritis |
| Alexander Kleinpeter | Microbiology | NIH R21 2 years | Elucidating the role of IP6 in HIV-1 assembly, maturation, and infection. |
| Brajesh Singh | Pediatrics | NIH R21 2 years | A membrane fusion apparatus trailblazes measles virus spread in airway cells |
David Weiss (Contact PI); Craig Ellermeier (MPI) | Microbiology | NIH R01 5 years | Defining the Structure and Function of a New Family of Peptidoglycan Crosslinking Enzymes |
| Other Awards | |||
| John Bernat | Pediatrics | Chiesi Farmaceutici S.p.A. 3 years | PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease |
| Naomi Fei | Internal Medicine | Henlius USA Inc. 3 years | HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer |
| Spyridon Fortis | Internal Medicine | GlaxoSmithKline, LLC 3 years | Anti-TSLP Antibody (GSK5784283) in Adults aged 18 to 75 years of age with Uncontrolled Asthma |
| Muhammad Furqan | Internal Medicine | BioNTech SE 3 years | BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer |
| Tara Graff | Internal Medicine | AbbVie, Inc. 3 years | Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORETMFL-2) |
| Tara Graff | Internal Medicine | Merck Sharp & Dohme LLC 3 years | Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL) |
| Tara Graff | Internal Medicine | Merck Sharp & Dohme LLC 3 years | A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating theEfficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus PolatuzumabVedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL). |
| Alan Gunderson | Internal Medicine | GigaGen Inc 3 years | GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants with Chronic Hepatitis B Virus Infection |
| Henry Hoffman | Internal Medicine | MeiraGTX, LLC 3 years | Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia |
| Matthew Krasowski | Pathology | CellaVision 2 years | CellaVision Clinical Studies of DI-90 |
| Yusuf Menda | Radiology | Novartis Pharmaceuticals Corporation 4 years | [225Ac] Ac-ETN029 in patients with Advanced DLL3-expressing Solid Tumors |
| Steven Moore | Pathology | Avidity Biosciences, Inc. 1 year | Avidity SOW 2 |
| Kenneth Nepple | Urology | Pfizer Medical Grants & Partnerships (GMGP) 2 years | AI-Enhanced Quality Improvement to Optimize Genetic Testing in Advanced Prostate Cancer |
| Dimah Saade | Pediatrics | REGENXBIO Inc. 3 years | Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD) |
| Tomohiro Tanaka | Internal Medicine | Bluejay Therapeutics, Inc. 3 years | BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1) |
| Hanna Zembrzuska | Internal Medicine | Zura Bio | Tibulizumab in Adults with Systemic Sclerosis |
May 2025New Federal Awards | |||
| Brad Amendt | Dental Research | NIH R56 1 year | Irx1 regulation of oral tissue repair and maintenance. |
| Competetive Renewal | |||
| Kris DeMali | Biochemistry & Molecular Biol | NIH R35 5 years | Molecular Mechanisms Underlying E-cadherin Mechanotransduction |
| Quanhathai Kaewpoowat | Internal Medicine | US Department of Health & Human Services, Health Resources & Services Administration 3 years | OP EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE |
| Other Awards | |||
| Po Hein Ear | Surgery | Neuroendocrine Tumor Rsearch Foundation 2 years | Role of NRF2 in SBNETs and development of a novel inhibitor |
| Mark Granner | Neurology | Neuron Therapeutics Inc 5 years | Inhibitory Interneurons (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Focal Seizures |
| Douglas Laux | Internal Medicine | OncoResponse 3 years | OR502 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies |
| Paul McCray | Pediatrics | Cystic Fibrosis Foundation 3 years | Optimizing Delivery of Prime Editors to Repair the CFTR F508del Mutation |
| Mohamad Mokadem | Internal Medicine | Novo Nordisk Pharmaceuticals, Inc. 3 years | Testing peripheral nervous system as mediators of the metabolic effects of Monlunabant |
| Eric Mou | Internal Medicine | Corvus Pharmaceuticals, Inc. 3 years | Soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL). |
| Sneha Phadke | Internal Medicine | BeOne Medicines USA, Inc. 4 years | BGB-21447 (Bcl-2i) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer |
| Edgar Samaniego | Neurology | Rapid Pulse 3 years | RapidPulseTM Aspiration System as Frontline Approach for Patients with Acute Ischemic Stroke due to Large Vessel Occlusions ("RapidPulse Pivotal Study") |
| Hira Shaikh | Internal Medicine | AstraZeneca Pharmaceuticals LP 3 years | GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 andB-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma |
| Patrick Sinn | Pediatrics | Cystic Fibrosis Foundation 3 years | Chimeric Adenoviral Vectors for Improved Base Editor Delivery to Primate Airways |
| Lucy Wibbenmeyer | Surgery | Skingenix Inc. 3 years | Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns. |
April 2025New Federal Awards | |||
| Nagalakshmi Balasubramanian | Cardiothoracic Surgery | NIH K99 2 years | Alcohol-Induced Metabolome-Epigenome Dysfunction and Alzheimer's Disease Risk |
| Ryan Boudreau | Internal Medicine | NIH R35 7 years | Genetic and Molecular Mechanisms of Heart Disease |
| Amanda Dudek | Microbiology | NIH R00 3 years | Mechanisms that Enhance and Suppress HIV-1 Resistance in Gene Edited Primary Human Cells |
| Amelia Hurley-Novatny | Orthopedic Surgery | NIH F30 4 years | Investigating the role of FGF21 in bone homeostasis in Duchenne Muscular Dystrophy |
| Nicholas Schnicker | Medicine Administration | NIH S10 1 year | Acquisition of 200 kV Glacios Cryo-TEM at the University of Iowa |
| Adele Stewart | Neuroscience & Pharmacology | NIH R21 2 years | Sex-biased, region-specific regulation of DA release and clearance |
| Robert Weiss | Internal Medicine | NIH S10 1 year | High Resolution Research Ultrasound |
| Competetive Renewal | |||
| Kalpaj Parekh | Cardiothoracic Surgery | NIH R01 4 years | Pathogenesis of Airway Stem Cell Abnormalities in Obliterative Bronchiolitis |
| Other Awards | |||
| Caryn Berkowitz | Internal Medicine | CorMedix Inc. 3 years | DefenCath in Reducing Central Line-Associated Bloodstream Infections (CLABSIs) in Adult Participants Receiving Total Parental Nutrition (TPN) via Central Venous Catheter (CVC) |
| Muhammad Furqan | Internal Medicine | Sanofi US Serices Inc. 3 years | SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors |
| Tara Graff | Internal Medicine | AstraZenica LP 4 years | AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkins Lymphoma (SOUNDTRACK-B) |
| James Holmes | Radiology | University of Virginia 1 year | Model Based Deep Learning Framework for Ultra-High Resolution Multi-Contrast MRI |
| Asad Javed | Internal Medicine | IDEAYA Biosciences Inc. 3 years | IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC infusions |
| Douglas Laux | Internal Medicine | Bicara Therapeutics 3 years | Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Vincent Magnotta | Radiology | University of Virginia 5 years | Fast Multi-dimensional Diffusion MRI with Sparse Sampling and Model-based Deep Learning Reconstruction |
| John Rieth | Internal Medicine | SERVIER Bio-Innovation LLC 3 years | Ivosidenib in participants 18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen |
| Edgar Samaniego | Neurology | Medtronic, Inc. 3 years | Clinical Investigation Plan of the Artisse Intrasaccular Device IDE |
| Edgar Samaniego | Neurology | Terumo Neuro 4 years | Complex Aneurysm Registry (CAR) Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices |
| Antonio Sanchez | Internal Medicine | 89bio, Inc. 4 years | Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (ENLIGHTEN-Fibrosis) |
| Jennifer Streeter | Internal Medicine | Asklepios BioPharmaceutical, Inc. | GenePHIT |
| Michael Tansey | Pediatrics | BioMarin Pharmaceutical, Inc. 3 years | Growth in Children with Idiopathic Short Stature |
March 2025New Federal Awards | |||
| Scott Moye-Rowley | Molecular Physiology & Biophysics | NIH R21 2 years | Nanobody-mediated proteolysis of Aspergillus fumigatus transcription factors in vitro and in vivo |
Robert Mullins (Contact PI);
| Ophthalmology and Visual Sci | NIH R01 5 years | Editing AMD Risk Alleles in Human Cells |
| Sarah Short | Internal Medicine | NIH R03 2 years | Epithelial specific roles for GPx1 in the intestinal microenvironment |
| Long-Sheng Song | Internal Medicine | NIH R01 3 years | Junctophilin-1 in the heart |
| Ian Thornell | Internal Medicine | NIH R01 4 years | Receptor-mediated Control of Pulmonary Ionocytes |
| Other Awards | |||
| Marcelo Correia | Internal Medicine | Novartis Pharmaceuticals Corporation | Evaluating INClisiran as a soLUtion to improve LDL-C management and cloSe care gaps in an Inclusive ASCVD and ASCVD risk equivalent population |
| John Engelhardt | Anatomy and Cell Biology | Recode Therapeutics Inc. | Recode Scope of Work No 2 |
| Umar Farooq | Internal Medicine | Celgene/ Bristol-Myers Squibb | JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (TRANSCEND FL) |
| Andrew Feider | Anesthesia | Massachusetts General Hospital | Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS II) |
| Alicia Gerke | Internal Medicine | Pulmovant, Inc. | Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease |
| Michael Hummel | Radiology | ABK Biomedical USA, Inc. | Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC) |
| Yusuf Menda | Radiology | Perspective Therapeutics | [212Pb]VMT--NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors |
| Kelly Mulfaul | Neuroscience & Pharmacology | Edward N. & Della L. Thome Memorial Foundation | Elucidating choroidal CCL5-CCR5 signaling to develop therapeutic targets for early AMD |
| John Rieth | Internal Medicine | PHILOGEN S.p.A. | Doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin along as first-line therapy in patients with metastatic leiomyosarcoma |
| Andrew Russo | Molecular Physiology & Biophys | Vedana Therapeutics, Inc. | Characterization of antibody and antibody-like molecules for their ability to reduce light-induced migraine-like phenotypes |
| Hanna Zembrzuska | Internal Medicine | Cullinan Therapeutics, Inc | CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)", CLN-978-SL-101 |
February 2025New Federal Awards | |||
Budd Tucker (Contact PI); Edwin Stone (MPI); Robert Mullins (MPI) | Ophthalmology and Visual Sci | NIH R01 5 years | Non-destructive assessment of retinal differentiation capacity and developmental maturity |
Mark Greiner (Contact PI): Aliasger Salem (MPI) | Ophthalmology and Visual Sci | NIH R01 5 years | Modulating Ferroptosis in Fuchs Endothelial Corneal Dystrophy |
| Competitive Renewal | |||
| Nandakumar Narayanan | Neurology | NIH R01 | Frontal Midline delta/theta rhythms and cognitive control in PD |
| Other Awards | |||
| Tara Graff | Internal Medicine | BeiGene Ltd. 3 years | Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia |
| Eric Mou | Internal Medicine | March Biosciences 6 years | MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL). |
| Lama Noureddine | Internal Medicine | Alexion Pharmaceuticals, Inc. 3 years | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) |
| Michael Tansey | Pediatrics | Novo Nordisk Pharmaceuticals, Inc. | Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly |
| Michael Wall | Ophthalmology and Visual Sci | AbbVie, Inc. 1 year | AGN-193408 SR in Participants with Open-Angle Glaucoma or Ocular Hypertension |
David Stolz (Contact PI); Daniel Cook, (MPI) | Internal Medicine | Cystic Fibrosis Foundation 3 years | Iowa CFF RDP Junior Faculty Recruitment Award |
January 2025New Federal Awards | |||
| Amy Ryan | Anatomy and Cell Biology | NSF 3 years | Collaborative Research: ENG-BIOTECH: Engineering Biomedical Systems to Investigate Extracellular Matrix Regulation of Airway Basal Cell Stemness and Differentiation |
Punam Saha (Contact PI); Alejandro Comellas Freymond (MPI) | Radiology | NIH R21 2 years | Osteoporosis and Sarcopenia in COPD and CT-based Phenotypes |
| Other Awards | |||
| Paari Dominic | Internal Medicine | Texas Cardiac Arrhythmia Research Foundation | Safety and efficacy of pulsed-field ablation for atrial fibrillation in high versus low-volume ablation centers (SAFFICIENT) |
| Naomi Fei | Internal Medicine | Planes Therapeutics, Inc. | PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab. |
| Henry Hoffman | Otolaryngology | RiboX Therapeutics, Ltd. (US) | RXRG001 to Parotid Gland(s) in Adults with Radiation-Induced Xerostomia and Hyposalivation |
| Katherine Mathews | Pediatrics | Avidity Biosciences, Inc. | AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD) |
Eric Taylor (Contact PI); Douglas Spitz (MPI) | Molecular Physiology | Nationwide Children's Hospital | Targeting Tubular Mitochondrial Superoxide Dismutation in Cisplatin Renal Repair |
| Christopher Strouse | Internal Medicine | Janssen Research & Development, Inc 5 years | JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma |
| Tracey Cho | Neurology | Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Forms of Multiple Sclerosis |
| Tracey Cho | Neurology | Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis |
| Katherine Mathews | Pediatrics | Avidity Biosciences, Inc 5 years | AOC 1044 Administered Intravenously to Healthy Adults |
| Val Sheffield | Pediatrics | CRISPR Therapeutics, Inc 2 years | MYOC gene editing for Myocilin Associated Glaucoma |